These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 7908218)

  • 81. Frequent loss of heterozygosity at the DCC locus in gastric cancer.
    Uchino S; Tsuda H; Noguchi M; Yokota J; Terada M; Saito T; Kobayashi M; Sugimura T; Hirohashi S
    Cancer Res; 1992 Jun; 52(11):3099-102. PubMed ID: 1591722
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Genetic studies of 457 breast cancers. Clinicopathologic parameters compared with genetic alterations.
    Harada Y; Katagiri T; Ito I; Akiyama F; Sakamoto G; Kasumi F; Nakamura Y; Emi M
    Cancer; 1994 Oct; 74(8):2281-6. PubMed ID: 7922980
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.
    Gong Y; Booser DJ; Sneige N
    Cancer; 2005 May; 103(9):1763-9. PubMed ID: 15786420
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
    Geisler S; Lønning PE; Aas T; Johnsen H; Fluge O; Haugen DF; Lillehaug JR; Akslen LA; Børresen-Dale AL
    Cancer Res; 2001 Mar; 61(6):2505-12. PubMed ID: 11289122
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Loss of heterozygosity on chromosomes 10 and 17 in clinically localized prostate carcinoma.
    Ittmann MM
    Prostate; 1996 May; 28(5):275-81. PubMed ID: 8610052
    [TBL] [Abstract][Full Text] [Related]  

  • 86. [Study of mdm2 gene amplification in primary breast tumors].
    Fontana X; Ferrari P; Abbes M; Monticelli J; Namer M; Bussière F
    Bull Cancer; 1994 Jul; 81(7):587-92. PubMed ID: 7742600
    [TBL] [Abstract][Full Text] [Related]  

  • 87. A gene expression signature identifies two prognostic subgroups of basal breast cancer.
    Sabatier R; Finetti P; Cervera N; Lambaudie E; Esterni B; Mamessier E; Tallet A; Chabannon C; Extra JM; Jacquemier J; Viens P; Birnbaum D; Bertucci F
    Breast Cancer Res Treat; 2011 Apr; 126(2):407-20. PubMed ID: 20490655
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Deletion of chromosome 17p loci in breast cancer cells detected by fluorescence in situ hybridization.
    Matsumura K; Kallioniemi A; Kallioniemi O; Chen L; Smith HS; Pinkel D; Gray J; Waldman FM
    Cancer Res; 1992 Jun; 52(12):3474-7. PubMed ID: 1350754
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Microsatellite analysis of loss of heterozygosity on chromosomes 9q, 11p and 17p in medulloblastomas.
    Albrecht S; von Deimling A; Pietsch T; Giangaspero F; Brandner S; Kleihues P; Wiestler OD
    Neuropathol Appl Neurobiol; 1994 Feb; 20(1):74-81. PubMed ID: 8208343
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Loss of heterozygosity in sporadic human breast carcinoma: a common region between 11q22 and 11q23.3.
    Hampton GM; Mannermaa A; Winqvist R; Alavaikko M; Blanco G; Taskinen PJ; Kiviniemi H; Newsham I; Cavenee WK; Evans GA
    Cancer Res; 1994 Sep; 54(17):4586-9. PubMed ID: 8062246
    [TBL] [Abstract][Full Text] [Related]  

  • 91. c-erbB-2 amplification in node-negative human breast cancer.
    Ro JS; el-Naggar A; Ro JY; Blick M; Frye D; Fraschini G; Fritsche H; Hortobagyi G
    Cancer Res; 1989 Dec; 49(24 Pt 1):6941-4. PubMed ID: 2573424
    [TBL] [Abstract][Full Text] [Related]  

  • 92. CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer.
    Caldeira JR; Prando EC; Quevedo FC; Neto FA; Rainho CA; Rogatto SR
    BMC Cancer; 2006 Mar; 6():48. PubMed ID: 16512896
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Loss of the 17p chromosomal region in a metastatic carcinoma of the prostate.
    Macoska JA; Powell IJ; Sakr W; Lane MA
    J Urol; 1992 Apr; 147(4):1142-6. PubMed ID: 1552612
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Somatic mutations and human breast cancer. A status report.
    Callahan R; Cropp CS; Merlo GR; Liscia DS; Cappa AP; Lidereau R
    Cancer; 1992 Mar; 69(6 Suppl):1582-8. PubMed ID: 1540899
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Chromosome 1 alterations in breast cancer: allelic loss on 1p and 1q is related to lymphogenic metastases and poor prognosis.
    Borg A; Zhang QX; Olsson H; Wenngren E
    Genes Chromosomes Cancer; 1992 Nov; 5(4):311-20. PubMed ID: 1283319
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Frequent loss Xq25 on the inactive X chromosome in primary breast carcinomas is associated with tumor grade and axillary lymph node metastasis.
    Piao Z; Malkhosyan SR
    Genes Chromosomes Cancer; 2002 Mar; 33(3):262-9. PubMed ID: 11807983
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Patterns of allele losses suggest the existence of five distinct regions of LOH on chromosome 17 in breast cancer.
    Kirchweger R; Zeillinger R; Schneeberger C; Speiser P; Louason G; Theillet C
    Int J Cancer; 1994 Jan; 56(2):193-9. PubMed ID: 8314300
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Oncogenesis in ovarian cancer.
    Børresen AL
    Acta Obstet Gynecol Scand Suppl; 1992; 155():25-30. PubMed ID: 1502889
    [TBL] [Abstract][Full Text] [Related]  

  • 99. TP53 mutation analyses on breast carcinomas: a study of paraffin-embedded archival material.
    Gretarsdottir S; Tryggvadottir L; Jonasson JG; Sigurdsson H; Olafsdottir K; Agnarsson BA; Ogmundsdottir H; Eyfjörd JE
    Br J Cancer; 1996 Aug; 74(4):555-61. PubMed ID: 8761369
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Association of genetic alterations on chromosome 17 and loss of hormone receptors in breast cancer.
    Ito I; Yoshimoto M; Iwase T; Watanabe S; Katagiri T; Harada Y; Kasumi F; Yasuda S; Mitomi T; Emi M
    Br J Cancer; 1995 Mar; 71(3):438-41. PubMed ID: 7880720
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.